Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Rhea-AI Summary
Altimmune (Nasdaq: ALT) announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website, with a replay available for up to three months after the call.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALT gained 0.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report Q3 2024 earnings?
What time is Altimmune's (ALT) Q3 2024 earnings call?
Where can I listen to Altimmune's (ALT) Q3 2024 earnings call?
